Transfusion Medicine Reviews
Volume 20, Issue 1 , Pages 27-33 , January 2006

The Role of Erythropoietin Therapy in the Critically Ill

  • Howard L. Corwin

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Howard L. Corwin, MD, Critical Care Medicine, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756.

References 

  1. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Crit. Care Med. 1999;27:2346–2350
  2. Rodriguez RM, Corwin HL, Gettinger A, et al. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J. Crit. Care. 2001;16:36–41
  3. Corwin HL, Abraham E, Fink MP, et al. Anemia and blood transfusion in the critically ill: Current clinical practice in the US—the CRIT study. Crit. Care Med. 2004;32:39–52
  4. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults: Pattern of use and effect on transfusion requirements. N. Engl. J. Med. 1986;314:1233–1235
  5. Corwin HL, Parsonnet KC, Gettinger A. RBC transfusion in the ICU. Is there a reason?. Chest. 1995;108:767–771
  6. Eyster E, Bernene J. Nosocomial anemia. JAMA. 1973;223:73–74
  7. Tarpey J, Lawler PG. Iatrogenic anaemia? A survey of venesection in patients in the intensive therapy unit. Anaesthesia. 1990;45:396–398
  8. von Ahsen N, Muller C, Serke S, et al. Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit. Care Med. 1999;27:2630–2639
  9. Vincent JL, Baron J-F, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288:1499–1507
  10. Burnum JF. Medical vampires. N. Engl. J. Med. 1986;314:1250–1251
  11. van Iperen CE, Gaillard CAM, Kraaijenhagen RJ, et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit. Care Med. 2000;28:2773–2778
  12. Gabriel A, Kozek S, Chiari A, et al. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J. Trauma. 1998;44:361–367
  13. Frede S, Fandrey J, Pagel H, et al. Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats. Am. J. Physiol. 1997;273:R1067–R1071
  14. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J. Interferon Cytokine Res. 1998;18:555–559
  15. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992;80:1639–1647
  16. Krantz SB. Pathogenesis and treatment of the anemia of chronic disease. Am. J. Med. Sci. 1994;307:353–359
  17. Corwin HL, Krantz SB. Anemia of the critically ill: “Acute” anemia of chronic disease. [editorial] Crit. Care Med. 2000;28:3098–3099
  18. Littenberg B, Corwin H, Leichter J, et al. A practice guideline and decision aid for blood transfusion. Immunohematology. 1995;11:88–94
  19. Groeger JS, Guntupalli KK, Strosberg M, et al. Descriptive analysis of critical care units in the United States: Patient characteristics and intensive care unit utilization. Crit. Care Med. 1993;21:279–291
  20. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N. Engl. J. Med. 1999;340:409–417
  21. Dietrich KA, Conrad SA, Hebert CA, et al. Cardiovascular and metabolic response to red blood cell transfusion in critically ill volume-resuscitated patients. Crit. Care Med. 1990;18:940–944
  22. Lorente JA, Landin L, De Pablo R, et al. Effects of blood transfusion on oxygen transport variables in sepsis. Crit. Care Med. 1993;21:1312–1318
  23. Marik PE, Sibbaid WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA. 1993;269:3024–3029
  24. Fitzgerald RD, Martin CM, Dietz GE, et al. Transfusing red blood cells stored in citrate phosphate dextrose adenine-1 for 28 days fails to improve tissue oxygenation in rats. Crit. Care Med. 1997;25:726–732
  25. Henry DH, Bowers P, Romano MT, et al. Epoetin alfa: Clinical evolution of a pleiotropic cytokine. Arch. Intern. Med. 2004;164:262–276
  26. Gabriel A, Kozek S, Chiari A, et al. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J. Trauma. 1998;44:361–367
  27. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA. 2002;288:2827–2835
  28. Silver M, Bazan A, Corwin HL, et al. A randomized double blind placebo controlled trial of recombinant human erythropoietin in long term acute care patients. Crit. Care Med. 2003;31:A167;(abstract, suppl)
  29. Eckardt K-U, Casadevall N. Pure red-cell aplasia due to antierythropoietin antibodies. Nephrol. Dial. Transplant. 2003;18:865–869
  30. Erbayraktar S, Yilmaz O, Gokmen N, et al. Erythropoietin is a multifactorial tissue-protective cytokine. Curr. Hematol. Rep. 2003;2:465–470
  31. Silverberg DS, Wexler D, Blurn M, et al. The use of subcutaneous erythropoietin intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class and markedly reduces hospitalization. J. Am. Coll. Cardiol. 2000;35:1737–1744
  32. Ehrenreich H, Hasselblatt M, Lewczuk P, et al. Erythropoietin treatment for acute stroke: A randomized double-blind proof-of-concept trial in man. Stroke. 2002;33:354
  33. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U. S. A. 2000;97:10526–10531
  34. Liu XZ, Xu XM, Hu R, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J. Neurosci. 1997;17:5395–5406
  35. Coleman T, Brines M. Recombinant human erythropoietin in critical illness: A role beyond anemia. Crit. Care. 2004;8:337–341
  36. Corwin HL, Hebert P. Avoiding a blood transfusion: How much is it worth?. Crit. Care Med. 2005;33:672–674
  37. Shermock KM, Horn E, Lipsett PA, et al. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit. Care Med. 2005;33:497–503
  38. Aubuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: Opportunities and controversies. Ann. Intern. Med. 1997;127:904–909
  39. Carson JL. Should patients in intensive care units receive erythropoietin?. JAMA. 2002;288:2884–2886
  40. Klein HG. Will blood transfusion ever be safe enough?. JAMA. 2000;284:238–240
  41. Jackson BR, Busch MP, Stramer SL, et al. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 2003;43:721–729
  42. Corwin HL, Aubuchon JP. Is leukoreduction of blood components for everyone?. JAMA. 2003;289:1993–1995

 Dr Corwin has received research support from Ortho Biotech and has served as a consultant for Ortho Biotech.

PII: S0887-7963(05)00079-9

doi: 10.1016/j.tmrv.2005.08.002

Transfusion Medicine Reviews
Volume 20, Issue 1 , Pages 27-33 , January 2006

Article Tools